New Insights & Approvals for Baricitinib

Baricitinib received its first approval from the European Commission in February 2017 for use across the EU.

Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

Eli Lilly and Company. News release: New safety and long-term efficacy data from baricitinib clinical trials in patients with moderate to severe rheumatoid arthritis. 2017 Jun 16.
Eli Lilly and Company. News release: Japan Ministry of Health, Labor and Welfare (MHLW) grants marketing approval for Olumiant (baricitinib) for the treatment of rheumatoid arthritis. 2017 Jul 3.
Fellow M. Eli Lilly arthritis drug outperforms Humira and receives NICE backing. Pharmafile.com. 2017 Jun 30

Brodalumab Approved for Plaque Psoriasis The U.S. Food and Drug Administration has approved brodalumab, a monoclonal antibody that targets interleukin 17 (IL‑17).1,2 Brodalumab (Siliq) was approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and have failed to respond to, or have lost response to, other…

In a recent study, baricitinib proved more effective than adalimumab in treating adults with RA through 52 weeks…

The phase 3, RA-BEAM study found RA patients who were switched from adalimumab to baricitinib experienced improvements in disease control even in the absence of an adalimumab washout. In the study, the change was not associated with an increase in adverse events or infections…

Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…

Brodalumab Approved for Plaque Psoriasis, Plus Baricitinib Effiicacy Studied for RA

Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

The Rescue: Moving RA Patients from Adalimumab to Baricitinib

Baricitinib Effective for Treating Refractory Rheumatoid Arthritis

Related Articles